Canadian Pharmacists Journal / Revue des Pharmaciens du Canada最新文献_第2页

Strategies to guide the successful implementation of deprescribing in community practice: Lessons learned from the front line 指导在社区实践中成功实施去处方化的策略：从第一线汲取的经验教训

Canadian Pharmacists Journal / Revue des Pharmaciens du Canada Pub Date : 2024-04-13 DOI: 10.1177/17151635241240737

Justin P. Turner, Kelda Newport, Aisling M. McEvoy, Tara Smith, Cara Tannenbaum, Deborah V. Kelly

{"title":"Strategies to guide the successful implementation of deprescribing in community practice: Lessons learned from the front line","authors":"Justin P. Turner, Kelda Newport, Aisling M. McEvoy, Tara Smith, Cara Tannenbaum, Deborah V. Kelly","doi":"10.1177/17151635241240737","DOIUrl":"https://doi.org/10.1177/17151635241240737","url":null,"abstract":"Sustainable implementation of new professional services into clinical practice can be difficult. In 2019, a population-wide initiative called SaferMedsNL was implemented across the province of Newfoundland and Labrador (NL), to promote appropriate medication use. Two evidence-based interventions were adapted to the context of NL to promote deprescribing of proton pump inhibitors and sedatives. The objective of this study was to identify and prioritize which actions supported the implementation of deprescribing in community practice for pharmacists, physicians and nurse practitioners across the province. Community pharmacists, physicians and nurse practitioners were invited to participate in virtual focus groups. Nominal Group Technique was used to elicit responses to the question: “What actions support the implementation of deprescribing into the daily workflow of your practice?” Participants prioritized actions within each group while thematic analysis permitted comparison across groups. Five focus groups were held in fall 2020 involving pharmacists ( n = 11), physicians ( n = 7) and nurse practitioners ( n = 4). Participants worked in rural ( n = 10) and urban ( n = 12) settings. The different groups agreed on what the top 5 actions were, with the top 5 receiving 68% of the scores: (1) providing patient education, (2) allocating time and resources, (3) building interprofessional collaboration and communication, (4) fostering patient relationships and (5) aligning with public awareness strategies. Pharmacists, physicians and nurse practitioners identified similar actions that supported implementing evidence-based deprescribing into routine clinical practice. Sharing these strategies may help others embed deprescribing into daily practice and assist the uptake of medication appropriateness initiatives by front-line providers. Can Pharm J (Ott) 2024;157:xx-xx.","PeriodicalId":9476,"journal":{"name":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140707411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Influenza vaccination in community pharmacy: A cross-sectional survey of Canadian adults’ knowledge, attitude and beliefs 社区药房的流感疫苗接种：加拿大成年人的知识、态度和信念横断面调查

Canadian Pharmacists Journal / Revue des Pharmaciens du Canada Pub Date : 2024-04-11 DOI: 10.1177/17151635241240464

S. Houle, Ajit Johal, Paul Roumeliotis, Bertrand Roy, Wendy Boivin

{"title":"Influenza vaccination in community pharmacy: A cross-sectional survey of Canadian adults’ knowledge, attitude and beliefs","authors":"S. Houle, Ajit Johal, Paul Roumeliotis, Bertrand Roy, Wendy Boivin","doi":"10.1177/17151635241240464","DOIUrl":"https://doi.org/10.1177/17151635241240464","url":null,"abstract":"In Canada, influenza vaccination rates are below recommended targets, with pharmacies the leading setting for vaccine administration. This work aimed to determine the Canadian public’s current knowledge, attitudes and practices related to pharmacy-based influenza vaccination services. We surveyed 3000 Canadian residents aged ≥18 years using a cross-sectional, self-reported, online structured questionnaire between December 5 and 21, 2022. A representative survey population was recruited from the Léger Opinion (LEO) consumer panel. Data were weighted by age, region and gender, based on 2021 census data. During the 2022–2023 season, 56.6% (95% confidence interval [CI], 54%-59.2%) of respondents reported receiving an influenza vaccine at a pharmacy, including 57.5% (95% CI, 54.2%-60.8%) of respondents considered to be at high risk of complications from influenza. Among respondents previously vaccinated at a pharmacy, 94.1% (95% CI, 91%-97.2%) were satisfied with the experience, citing convenience, accessibility and availability as factors influencing their decision. Among all respondents, 29.3% (95% CI, 27.5%-31.1%) reported that a pharmacist’s recommendation for the influenza vaccine would affect their decision to be vaccinated, yet only 10.4% (95% CI, 5.9%-15%) who had discussions with a pharmacist specifically discussed the importance of influenza vaccination. Canadians are satisfied with pharmacy-based influenza vaccinations and value pharmacist recommendations. Pharmacists have an opportunity to boost influenza vaccination coverage in Canada by providing counselling on the importance of influenza vaccination to those seeking their advice on other health care needs, including younger adults and those with risk factors for serious illness from influenza.","PeriodicalId":9476,"journal":{"name":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140712882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

“Are you sure you want to be a pharmacist?” "你确定要当药剂师吗？"

Canadian Pharmacists Journal / Revue des Pharmaciens du Canada Pub Date : 2024-04-11 DOI: 10.1177/17151635241241044

Kevin Ta

引用次数: 0

Developing pharmacy leaders: A design thinking approach to navigate the leadership crisis in pharmacy 培养药学领导者：以设计思维方法应对药学领导力危机

Canadian Pharmacists Journal / Revue des Pharmaciens du Canada Pub Date : 2024-04-09 DOI: 10.1177/17151635241240470

Kayla Byers, Angela Gee, M. Anwar

引用次数: 0

Do we need to separate pharmacy advocacy organizations? 我们需要将药房宣传组织分开吗？

Canadian Pharmacists Journal / Revue des Pharmaciens du Canada Pub Date : 2024-04-09 DOI: 10.1177/17151635241241039

Shania Liu, Ross T. Tsuyuki

引用次数: 0

Health human resources planning in Canada—Part II: Its importance for pharmacy in Canada 加拿大卫生人力资源规划--第二部分：其对加拿大药房的重要性

Canadian Pharmacists Journal / Revue des Pharmaciens du Canada Pub Date : 2024-03-28 DOI: 10.1177/17151635241239884

Natalie Crown, I. Bourgeault, Z. Austin

引用次数: 0

A new curricular framework for an interprofessional approach to deprescribing: Why and how pharmacists should lead the way 针对取消处方的跨专业方法的新课程框架：药剂师为何以及如何发挥带头作用

Canadian Pharmacists Journal / Revue des Pharmaciens du Canada Pub Date : 2024-03-15 DOI: 10.1177/17151635241239924

Brenda G. Schuster, Sadaf Faisal, Camille L. Gagnon

引用次数: 0

Medical assistance in dying: A reflection tool for pharmacists 临终医疗救助：药剂师的思考工具

Canadian Pharmacists Journal / Revue des Pharmaciens du Canada Pub Date : 2024-02-15 DOI: 10.1177/17151635241228215

J. Navarrete, Margaret Gray, Michelle A. King, Amary Mey, Phillip Woods, Theresa J. Schindel

引用次数: 0

An economic evaluation of community pharmacy dispensed naloxone in Canada 加拿大社区药房配发纳洛酮的经济评估

Canadian Pharmacists Journal / Revue des Pharmaciens du Canada Pub Date : 2024-02-13 DOI: 10.1177/17151635241228241

Ashley Cid, Nikita Mahajan, William W.L. Wong, Michael Beazely, K. Grindrod

{"title":"An economic evaluation of community pharmacy dispensed naloxone in Canada","authors":"Ashley Cid, Nikita Mahajan, William W.L. Wong, Michael Beazely, K. Grindrod","doi":"10.1177/17151635241228241","DOIUrl":"https://doi.org/10.1177/17151635241228241","url":null,"abstract":"To determine the cost-effectiveness of pharmacy-based intranasal (IN) and intramuscular (IM) naloxone distribution in Canada. We developed a state-transition model for pharmacy-based naloxone distribution, every 3 years, to illicit, prescription, opioid-agonist therapy and nonopioid use populations compared to no naloxone distribution. We used a monthly cycle length, lifetime horizon and a Canadian provincial Ministry of Health perspective. Transition probabilities, cost and utility data were retrieved from the literature. Costs (2020) and quality-adjusted life years (QALY) were discounted 1.5% annually. Microsimulation, 1-way and probabilistic sensitivity analyses were conducted. Distribution of naloxone to all Canadians compared to no distribution prevented 151 additional overdose deaths per 10,000 persons, with an incremental cost-effectiveness ratio (ICER) of $50,984 per QALY for IM naloxone and an ICER of $126,060 per QALY for IN naloxone. Distribution of any naloxone to only illicit opioid users was the most cost-effective. One-way sensitivity analysis showed that survival rates for illicit opioid users were most influenced by the availability of either emergency medical services or naloxone. Distribution of IM and IN naloxone to all Canadians every 3 years is likely cost-effective at a willingness-to-pay threshold of $140,000 Canadian dollars/QALY (~3 × gross domestic product from the World Health Organization). Distribution to people who use illicit opioids was most cost-effective and prevented the most deaths. This is important, as more overdose deaths could be prevented through nationwide public funding of IN naloxone kits through pharmacies, since individuals report a preference for IN naloxone and these formulations are easier to use, save lives and are cost-effective. Can Pharm J (Ott) 2024;157:xx-xx.","PeriodicalId":9476,"journal":{"name":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139781734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An economic evaluation of community pharmacy dispensed naloxone in Canada 加拿大社区药房配发纳洛酮的经济评估

Canadian Pharmacists Journal / Revue des Pharmaciens du Canada Pub Date : 2024-02-13 DOI: 10.1177/17151635241228241

Ashley Cid, Nikita Mahajan, William W.L. Wong, Michael Beazely, K. Grindrod

{"title":"An economic evaluation of community pharmacy dispensed naloxone in Canada","authors":"Ashley Cid, Nikita Mahajan, William W.L. Wong, Michael Beazely, K. Grindrod","doi":"10.1177/17151635241228241","DOIUrl":"https://doi.org/10.1177/17151635241228241","url":null,"abstract":"To determine the cost-effectiveness of pharmacy-based intranasal (IN) and intramuscular (IM) naloxone distribution in Canada. We developed a state-transition model for pharmacy-based naloxone distribution, every 3 years, to illicit, prescription, opioid-agonist therapy and nonopioid use populations compared to no naloxone distribution. We used a monthly cycle length, lifetime horizon and a Canadian provincial Ministry of Health perspective. Transition probabilities, cost and utility data were retrieved from the literature. Costs (2020) and quality-adjusted life years (QALY) were discounted 1.5% annually. Microsimulation, 1-way and probabilistic sensitivity analyses were conducted. Distribution of naloxone to all Canadians compared to no distribution prevented 151 additional overdose deaths per 10,000 persons, with an incremental cost-effectiveness ratio (ICER) of $50,984 per QALY for IM naloxone and an ICER of $126,060 per QALY for IN naloxone. Distribution of any naloxone to only illicit opioid users was the most cost-effective. One-way sensitivity analysis showed that survival rates for illicit opioid users were most influenced by the availability of either emergency medical services or naloxone. Distribution of IM and IN naloxone to all Canadians every 3 years is likely cost-effective at a willingness-to-pay threshold of $140,000 Canadian dollars/QALY (~3 × gross domestic product from the World Health Organization). Distribution to people who use illicit opioids was most cost-effective and prevented the most deaths. This is important, as more overdose deaths could be prevented through nationwide public funding of IN naloxone kits through pharmacies, since individuals report a preference for IN naloxone and these formulations are easier to use, save lives and are cost-effective. Can Pharm J (Ott) 2024;157:xx-xx.","PeriodicalId":9476,"journal":{"name":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139841419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0